Cowen and Company’s Novo Nordisk NVO Stock Holding History

Cowen and Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,200	Closed	-$260K	–	668
2021 Q2	$260K	Buy	+6,200	New	+$240K	0.01%	246

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cowen and Company's NVO Position: Q3 2021 in Review

Cowen and Company sold out of Novo Nordisk (NVO) in Q3 2021, closing a stake of 6,200 shares — an estimated $260K sold.

Cowen and Company first reported a position in NVO in Q2 2021 and held it in 1 quarter. The position peaked at $260K in Q2 2021. 804 funds tracked by Wall St. Rank hold NVO as of Q3 2021.

Cowen and Company reported no remaining Novo Nordisk position as of Q3 2021 after selling out during the quarter.
Cowen and Company sold 6,200 Novo Nordisk shares in Q3 2021, an estimated $260K.
Cowen and Company first reported a position in Novo Nordisk in Q2 2021 and held it in 1 quarter.
Cowen and Company's Novo Nordisk position peaked at $260K in Q2 2021.
804 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.